What is Absci?
Absci is a biotechnology company headquartered in Vancouver, Washington, dedicated to advancing the creation of protein-based drugs and engineered biologics. The firm leverages its expertise in protein engineering and synthetic biology to develop novel therapeutic candidates and optimize production processes. By focusing on engineered E. coli for protein and antibody production, Absci aims to accelerate the discovery and development of next-generation biologics, addressing critical needs in the pharmaceutical and healthcare industries. The company's mission is to unlock the full potential of these advanced biological solutions.
How much funding has Absci raised?
Absci has raised a total of $286.9M across 7 funding rounds:
Series A
$5.1M
Series C
$12M
Multiple Rounds
$80.8M
Other Financing Round
$125M
Other Financing Round
$64M
Series A (2016): $5.1M with participation from Phoenix Venture Partners and Oregon Venture Fund
Series C (2018): $12M led by Greenbridge Partners, Phoenix Venture Partners, and Oregon Venture Fund
Series D (2020): $15.4M supported by JSR Life Sciences, Phoenix Venture Partners, KBI Biopharma, Oregon Venture Fund, Washington Research Foundation, and Columbia Ventures Corporation
Debt (2020): $350K featuring PPP
Series E (2020): $65M backed by Casdin Capital
Other Financing Round (2021): $125M with participation from Casdin Capital , LLC and Redmile Group , LLC
Other Financing Round (2025): $64M, investors not publicly disclosed
Key Investors in Absci
Greenbridge Partners
Greenbridge Partners is an investment firm based in Dublin, Ireland, specializing in sustainable investment solutions for individuals and businesses seeking to grow their portfolios responsibly.
Phoenix Venture Partners
Phoenix Venture Partners is a venture capital firm focused on transforming innovative technologies into market-ready products across advanced materials, novel devices, and manufacturing processes, supporting visionary entrepreneurs.
Oregon Venture Fund
Oregon Venture Fund invests in and supports growth-stage companies with ambitious founding teams, aiming to empower local entrepreneurs and scale businesses globally while fostering community impact.
What's next for Absci?
With the recent infusion of capital, Absci is poised for significant advancements in its research and development pipeline. The enterprise-level funding suggests a strategic focus on scaling operations, expanding its technological capabilities, and potentially forging new partnerships within the biopharmaceutical ecosystem. This investment will likely enable Absci to accelerate the clinical translation of its drug candidates and solidify its position as a leader in synthetic biology and protein engineering for therapeutic applications. The company's trajectory indicates a strong emphasis on innovation and market penetration.
See full Absci company page
